by David Rubin | Sep 23, 2024 | In the Press
A University of Chicago Medicine patient became the first person with ulcerative colitis in the world to receive the drug guselkumab (Tremfya) since its Sept. 11 approval by the FDA for treating moderate to severe ulcerative colitis. Tremfya has been used for many...
by David Rubin | May 4, 2021 | In the Press
Click here for the full video of Drs. Rubin, Siegel, Melmed, and Horrigan discussing the safety and efficacy of COVID-19 vaccines for patients with inflammatory bowel disease.
by David Rubin | Apr 29, 2021 | In the Press
Click here to watch Dr. Rubin discuss the advances in anti-cytokine therapy and receive AANP, AAPA, CME, CNE, CPE, or participation credit.
by David Rubin | Apr 19, 2021 | In the Press
Watch this video exclusive, to hear David T. Rubin, MD highlight how the COVID-19 pandemic changed the use of social media.
by David Rubin | Apr 18, 2021 | Coronavirus, Rubin's Reflections
Tweetorial to Clarify the NYT Article From 15 April and Further Explain/Clarify the UK CLARITY IBD Study David T. Rubin View Twitter Thread I’ve previously commented about the CLARITY IBD Study (Kennedy, et al). paper in this forum, but it bears repeating and...